跳至主要内容
临床试验/jRCT2053210130
jRCT2053210130招募中不适用

Evaluation of efficacy and safety of autologous bone marrow mesenchymal stem cells for traumatic spinal cord injury: Use-results comparative survey

NIPRO CORPORATION0 个研究点目标入组 612 人开始时间: 2019年5月16日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
612
主要终点
Percentage of the case with 1 or more levels of AIS improvement

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
No limit 至 No limit(—)
性别
All

入选标准

  • (1) Patients using autologous mesenchymal stem cells derived from bone marrow for the first time for traumatic spinal cord injury
  • (2) Patients or their surrogates must provide informed consent before the start

排除标准

  • 未提供

结局指标

主要结局

Percentage of the case with 1 or more levels of AIS improvement

时间窗: from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury

Percentage of the case with 1 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in **AIS B or C patients aged 20 to 70 years with traumatic cervial spinal cord injury**

Percentage of the case with 2 or more levels of AIS improvement

时间窗: from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury

Percentage of the case with 2 or more levels of AIS improvement from 6-8 weeks (49 +/- 7 days) to 180 days +/- 30 days after injury in **AIS A patients aged 20 to 70 years with traumatic cervial spinal cord injury**

次要结局

未报告次要终点

研究者

相似试验